NEW YORK, May 10 (Reuters) – Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the fate of WeightWatchers, which declared bankruptcy this week, citing vastly increased use of the new blockbuster medicines.

But some of WeightWatchers’ closest rivals, newer telehealth companies, face a new challenge of their own as federal regulators crack down on the cheaper versions of Novo Nordisk’s (NOVOb.CO), opens new tab Wegovy and Eli Lilly’s (LLY.N), opens new tab Zepbound that have become a big part of the companies’ sales. The telehealth companies’ success may ultimately depend on partnering with the name brand drugmakers, one analyst said.WeightWatchers filed for bankruptcy on Tuesday, as Americans shunned its weight management business in favor of the Novo and Lilly drugs and copies from pharmacies that can cut a person’s weight by 15%-20%. The drugs, from a class of digestion-slowing medicines known as GLP-1 agonists, have eaten into demand at some big companies, including Walmart’s (WMT.N), opens new tab food business.

WeightWatchers, when it filed for bankruptcy, said its weight management system stopped being attractive to customers given changing views about weight versus wellness, competition from telehealth companies fully embracing the weight-loss drugs, and even fitness influencers on TikTok. The company has an agreement with creditors to restructure its debt and quickly exit the court process. mackenzie davis nude mary-kay Kärna Fintrix

The organization is now calling on the government to set specific targets to reduce the number of preventable asthma deaths in the UK. These targets would help to drive improvements in asthma care, ensure better access to life-saving treatments, and ultimately save lives.

Asthma + Lung UK also stresses the importance of improving awareness and education about asthma among healthcare professionals, patients, and the general public. By increasing understanding of asthma and its symptoms, more people can receive timely and appropriate care, reducing the risk of severe asthma attacks and fatalities.

It is crucial that the government takes action to address the continuing issue of preventable asthma deaths in the UK. By setting clear targets and implementing measures to improve asthma care, we can work towards reducing the number of lives lost to this condition and ensuring that all individuals with asthma receive the support and treatment they need. Alza Fintrion